Patents by Inventor Hagen Von Briesen
Hagen Von Briesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200230054Abstract: The present invention relates generally to a sensor for tumor tissue and a local release system for releasing therapeutic agents/diagnostic agents for targeted tumor therapy and diagnosis. More specifically, the invention relates to a cation-stabilised biopolymer gel, in particular an alginate gel, for use as a carrier matrix for a tumor therapeutic agent and/or tumor diagnostic agent, characterised in that the gel destabilises in the presence of a stimulus, in particular lysyl oxidase (LOX), generated by tumor cells or tumor tissue and the tumor therapeutic agent and/or tumor diagnostic agent can be released, and a pharmaceutical composition that comprises this cation-stabilised biopolymer gel with incorporated tumor therapeutic agent and/or tumor diagnostic agent and optionally an additional reporter substance.Type: ApplicationFiled: January 18, 2018Publication date: July 23, 2020Inventors: Heiko ZIMMERMANN, Hagen VON BRIESEN, Andre SCHULZ, Linda ELBERSKIRCH, Sylvia WAGNER, Benjamin FISCHER
-
Patent number: 9211283Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.Type: GrantFiled: November 8, 2010Date of Patent: December 15, 2015Assignee: Biolitec Pharma Marketing LtdInventors: Klaus Langer, Matthias Wacker, Beate Röder, Annegret Preuss, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
-
Patent number: 8945924Abstract: A targeted cultivation phase adjustment is provided in a process for the cultivation of cells in which biological cells are cultivated on at least one boundary surface between different, non-solid cultivation phases so that pre-determined cultivation conditions are given. A cultivation apparatus (100) for biological cells is also provided that includes a culture container (10) with different, non-solid cultivation phases (20) between which at least one boundary surface is formed.Type: GrantFiled: February 7, 2007Date of Patent: February 3, 2015Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.Inventors: Günter R. Fuhr, Hagen Von Briesen, Erwin Gorjup, Charli Kruse
-
Patent number: 8671783Abstract: An adapter device includes a receptacle including at least one receiving element that detachably secures a sample chamber for cryoconservation of a biological sample, and a coupling device that connects the receptacle to a base section which can be secured in a cooling device, wherein the receiving element is 1) immobile in a holding state at a cryoconservation temperature and secures the sample chamber and 2) at least one of deformable and movable in a release state at a temperature above the cryoconservation temperature so that the sample chamber is detachable from the adapter device or can be inserted into the adapter device.Type: GrantFiled: June 3, 2009Date of Patent: March 18, 2014Assignee: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventors: Günter R. Fuhr, Heiko Zimmermann, Hagen von Briesen, Anja Germann
-
Publication number: 20120263739Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.Type: ApplicationFiled: October 21, 2010Publication date: October 18, 2012Applicant: MERCK PATENT GMBHInventors: Klaus Langer, Marion Anhorn, Joerg Kreuter, Florian Rothweiler, Hagen von Briesen, Sylvia Wagner, Martin Michaelis, Jindrich Cinatl
-
Publication number: 20110308333Abstract: An adapter device includes a receptacle including at least one receiving element that detachably secures a sample chamber for cryoconservation of a biological sample, and a coupling device that connects the receptacle to a base section which can be secured in a cooling device, wherein the receiving element is 1) immobile in a holding state at a cryoconservation temperature and secures the sample chamber and 2) at least one of deformable and movable in a release state at a temperature above the cryoconservation temperature so that the sample chamber is detachable from the adapter device or can be inserted into the adapter device.Type: ApplicationFiled: June 3, 2009Publication date: December 22, 2011Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Günter R. Fuhr, Heiko Zimmermann, Hagen von Briesen, Anja Germann
-
Publication number: 20110275686Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers, whose efficacy and safety are enhanced by such nanoparticulate formulations. It also teaches the method of preparing PLGA-based nanoparticles under sterile conditions. In one of the preferred embodiments of the present invention PLGA-based nanoparticles have a mean particle size less than 500 nm and the photosensitizer is temoporfin, 5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPC).Type: ApplicationFiled: November 8, 2010Publication date: November 10, 2011Inventors: Klaus Langer, Thomas Knobloch, Beate Röder, Annegret Preuß, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
-
Publication number: 20110142948Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.Type: ApplicationFiled: November 8, 2010Publication date: June 16, 2011Inventors: Klaus Langer, Matthias Wacker, Beate Röder, Annegret Preuss, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
-
Publication number: 20090029470Abstract: A targeted cultivation phase adjustment is provided in a process for the cultivation of cells in which biological cells are cultivated on at least one boundary surface between different, non-solid cultivation phases so that pre-determined cultivation conditions are given. A cultivation apparatus (100) for biological cells is also provided that includes a culture container (10) with different, non-solid cultivation phases (20) between which at least one boundary surface is formed.Type: ApplicationFiled: February 7, 2007Publication date: January 29, 2009Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Günter R. Fuhr, Hagen Von Briesen, Erwin Gorjup, Charli Kruse
-
Publication number: 20080095857Abstract: A carrier system in the form of protein-based nanoparticles for the cell-specific, intracellular enrichment of at least one pharmacologically active substance. The system has structures that are coupled by reactive groups. The structures enable a cell-specific attachment and cellular absorption of the nanoparticles.Type: ApplicationFiled: March 2, 2005Publication date: April 24, 2008Applicant: LTS LOHMANN THERAPIE-SYSTEME AG LOHMANNSTRASSE 2Inventors: Sabine Balthasar, Hagen Von Briesen, Norbert Dinauer, Jorg Kreuter, Klaus Langer, Heidrun Wartlick
-
Patent number: 6248328Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.Type: GrantFiled: February 25, 1999Date of Patent: June 19, 2001Assignee: Chemotherapeutisches ForschungsinstitutInventors: Ursula Dietrich, Hagen Von Briesen, Manuel Grez, Helga Rubsamen-Waigmann
-
Patent number: 5965135Abstract: Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.Type: GrantFiled: April 20, 1995Date of Patent: October 12, 1999Assignee: Chemotherapeutisches ForschungsinstitutInventors: Ursula Dietrich, Hagen Von Briesen, Manuel Grez, Helga Rubsamen-Waigmann
-
Patent number: 5861243Abstract: Vaccine for protection against HIV infections, therapeutic agents for treatment subsequent to HIV infections, process for their preparation and their use; procedure for differentiation between HIV-2.sub.ALT type infections and HIV-2 infections defined by the prototype HIV-2.sub.ROD.Subject matter of the present invention are the virus HIV-2.sub.D205 as well as HIV-2 variants distinguishing from the HIV-2 prototypes of the type HIV-2.sub.ROD in that nucleotide sequence homology is less than 77%. Further, proteins and nucleic acids of HIV-2.sub.D205 and its variants for utilization as vaccines for protection against HIV infections, for geno- or immunotherapy, for establishing an animal model, and for differential diagnostics are part of this invention. Furthermore, the processes for preparing these vaccines, immunotherapeutic and diagnostic agents as well as their use are part of this invention.Type: GrantFiled: November 12, 1997Date of Patent: January 19, 1999Assignee: Chemotherapeutisches Forschunginstitut Georg Speyer-Haus Zu Frankfurt A.M.Inventors: Ursula Dietrich, Michalina Adamski, Hagen Von Briesen, Herbert Kuhnel, Helga Rubsamen-Waigmann
-
Patent number: 5677147Abstract: HIV-2 virus variants, namely virus HIV D194 and virus HIV D205, which can be cloned from the corresponding virus isolate HIV D194 (ECACC V 87122303) or from the infected cell line HUT 194 (ECACC V 87122306) or from the virus isolate HIV D205 (ECACC V 87122304), respectively, and their RNA or RNA-fragments and DNA and DNA-fragments derived therefrom and/or proteins and the use thereof for diagnostics and therapy.Type: GrantFiled: July 22, 1996Date of Patent: October 14, 1997Assignees: Qiagen GmbH, Chemotherapeutisches Forschunginstitut Georg-Speyer-HausInventors: Karsten Henco, Hagen von Briesen, Andreas Immelmann, Herbert Kuhnel, Ursula Dietrich, Helga Rubsamen-Waigmann, Michalina Adamski
-
Patent number: 5637455Abstract: HIV-2 virus variants, namely virus HIV D194 and virus HIV D205, which can be cloned from the corresponding virus isolate HIV D194 (ECACC V 87122303) or from the infected cell line HUT 194 (ECACC V 87122306) or from the virus isolate HIV D205 (ECACC V 87122304), respectively, and their RNA or RNA-fragments and DNA and DNA-fragments derived therefrom and/or proteins and the use thereof for diagnostics and therapy.Type: GrantFiled: December 14, 1994Date of Patent: June 10, 1997Assignees: Qiagen GmbH, Chemotherapeutisches Forschunginstitut Georg-Speyer-HausInventors: Karsten Henco, Hagen von Briesen, Andreas Immelmann, Herbert Kuhnel, Ursula Dietrich, Helga Rubsamen-Waigmann, Michalina Adamski